Better regulation needed for kids' flu vaccine

April 15, 2013 by Carley Tonoli, The Conversation
CSL TIV is no longer recommended for children less than five years of age in Australia. Credit:

Flu vaccines given to children should be more rigorously tested before before being allowed onto the market, researchers say, to prevent a repeat of the 2010 vaccine release, which caused a spate of high fevers and febrile convulsions in young children.

The paper, published in the Medical Journal of Australia, reviews the regulatory history of CSL Fluvax trivalent (TIV) in Australia and overseas and recommends a tougher to protect .

Australian estimate that the risk of febrile convulsions in young children after vaccination with CSL TIV ranged from three to ten per 1,000 children vaccinated in Australia, before the program was suspended in April 2010.

As a result, CSL TIV is no longer recommended for children less than five years of age in Australia, the United States and the United Kingdom.

The paper reports that in 2002 thiomersal-free CSL TIV was approved for use in Australia in people aged six months and older, even though no controlled clinical studies had been conducted in children.

"Ideally, adequately powered, controlled paediatric studies should be conducted before a is licensed for children," study authors Health Kelly and Nicholas Kelley say in the paper.

The first and only randomised to date commenced in 2005 and was reported on in 2009, seven years after the vaccine was licensed for children in Australia.

The paper re-examined the data from that trial, which involved 298 children, aged less than nine years, who each received two doses of the 2005 formulation of TIV and a "booster" of the 2006 formulation, which had different virus antigens.

"The study results, published in 2009, showed a marked difference between the risk of reported fever, depending on the annual formulation of the CSL TIV administered," the new paper said.

Once a is licensed for use in Australia, the manufacturer is able to alter the formulation of the vaccine each year to protect against new flu strains that may be circulating.

Professor Robert Booy, Professor and Head of Clinical Research, National Centre for Immunisation Research and Surveillance (NCIRS) at University of Sydney said this was an important paper that deserved recognition.

"More research is needed before flu vaccines are introduced," he said.

"At NCIRS we have been conducting a systematic review of all relevant literature, published or not.

"We hope the various pharmaceutical companies will cooperate with us in providing anonymised individual level data."

Professor Booy said he agreed with the authors that thorough post-marketing monitoring for adverse events after all paediatric flu vaccines was essential and proposed an integrated yearly study involving at least 1,000 per year for the next three years.

Professor Anton Middelberg, Deputy Director of The Australian Institute for Bioengineering and Nanotechnology at the The University of Queensland said the study served as a reminder of the need to strictly control vaccine manufacture processes.

"Vaccine quality, and adverse effects, have on occasion been linked to variations in batch-to-batch manufacture," Professor Middelberg said.

"Subtle changes in process conditions can magnify in a chaotic fashion to compromise product quality, if not fundamentally understood and strictly controlled," he said.

"The problems become more acute when old technology is pushed to operate more quickly than it is designed to do, for example, when we are faced with a pandemic.

"There is a clear need for new, quicker and better-understood vaccine manufacture technology."

Explore further: Any prime-boost mix of injected or spray flu vaccine shields toddlers

More information: … es-control-influenza

Related Stories

Any prime-boost mix of injected or spray flu vaccine shields toddlers

August 16, 2011
Children younger than 3 years old receive the same protective antibody response from the recommended two doses of licensed seasonal influenza vaccines regardless of whether the two doses are injected by needle, inhaled through ...

FDA approves flu vaccine for coming season

August 14, 2012
(HealthDay) -- The formulation for the vaccine that will help protect against the flu this coming season was approved by the U.S. Food and Drug Administration on Monday.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.